European Alliance of Associations for Rheumatology Annual Congress (EULAR 2025)

Barcelona, Spain 11 June 2025 - 14 June 2025

MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis

27 Jun 2025 by

Apremilast, an oral immunomodulating phosphodiesterase-4 inhibitor, reduces inflammation in individual joints and clinical dactylitis as per MRI in patients with psoriatic arthritis (PsA), according to the results of a dynamic contrast-enhanced MRI (DCE-MRI) analysis of the phase IV, open-label MOSAIC study.

MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis

27 Jun 2025

Add-on obinutuzumab yields robust treatment benefit in lupus nephritis

26 Jun 2025 by

In a post hoc analysis using the phase III REGENCY study dataset, obinutuzumab on top of standard therapy (ST) demonstrates significant superiority to placebo plus ST across numerous renal response definitions in patients with active lupus nephritis (LN).

Add-on obinutuzumab yields robust treatment benefit in lupus nephritis

26 Jun 2025